Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03934840 2024-02-28

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase 2 Active not recruiting

22 enrolled

Genitourinary

Prostatic Neoplasms

NCT05707468 2024-02-20

Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

Phase NA Not yet recruiting

200 enrolled

Genitourinary

Oligometastatic Prostate Carcinoma

NCT06198387 2024-01-10

Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer

Phase NA Not yet recruiting

30 enrolled

Genitourinary

Oligo-metastatic Prostate Carcinoma

NCT06134271 2023-11-18

RASTOM

Phase 2 Not yet recruiting

160 enrolled

Genitourinary

Prostatic Neoplasms

NCT01949337 2023-09-28

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Phase 3 Unknown

1,311 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT05705700 2023-02-27

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

Phase 2 Unknown

30 enrolled

Neoadjuvant Therapy

NCT02789878 2022-09-15

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Phase 2 Completed

64 enrolled

Genitourinary

Prostatic Neoplasms

NCT01780220 2022-05-19

CARLHA

Phase 1/2 Completed

47 enrolled

Genitourinary

Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy

NCT03295565 2022-04-15

OSTRICh

Phase 2/3 Completed

100 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05188911 2022-01-12

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Unknown

30 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01574937 2021-08-06

XL-184+Abiraterone in Post-Chemo CRPC

Phase 1 Completed

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT02867020 2021-07-07

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Phase 2 Completed

128 enrolled

Genitourinary

Prostatic Neoplasms

NCT04839055 2021-04-09

CoA-CRPC

Phase 1/2 Unknown

50 enrolled

Genitourinary

Castration-resistant Prostate Cancer

NCT03418324 2020-12-30

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Phase 2 Completed

11 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT02883166 2020-12-07

SNACK

Phase 1 Completed

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT03173859 2020-11-18

AERA

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02036060 2020-11-16

ABIDO

Phase 2 Completed

119 enrolled

Genitourinary

Prostatic Neoplasms

NCT02429193 2020-01-13

BARRIER-P

Phase 2 Completed

16 enrolled

Genitourinary

Castration-resistant Prostate Cancer

NCT03644303 2019-11-14

TRAP

Phase NA Unknown

84 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Phase 2 Terminated

1 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

AASUR in High Risk Prostate Cancer

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

uPARCRPC

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

DIVINE

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

ProBio

Physical Function During ARSI Treatment

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer

RASTOM

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

CARLHA

OSTRICh

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

XL-184+Abiraterone in Post-Chemo CRPC

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

CoA-CRPC

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

SNACK

AERA

ABIDO

BARRIER-P

TRAP

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases